DECODING THE RISK PROFILE OF NON-ALCOHOLIC FATTY LIVER DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
DOI:
https://doi.org/10.22159/ajpcr.2025v18i1.53230Keywords:
Non-alcoholic fatty liver diseaseNon-alcoholic fatty liver disease, Non-alcoholic steatohepatitis, Type 2 diabetes mellitus, Hypertension, Obesity, Metabolic syndromeAbstract
Objective: This is a systematic review and meta-analysis that aims to evaluate the prevalence of non-alcoholic fatty liver disease (NAFLD) and the risk factors such as type 2 diabetes mellitus (T2DM), hypertension, obesity, PCOS, and sleep apnea associated with it. NAFLD is one of the most prevalent diseases that affect approximately 40% of diabetic, hypertensive, dyslipidemic obese individuals. Its asymptomatic nature often leads to under diagnosis and progress to severe liver cirrhosis and hepatocellular carcinoma.
Methods: A total of 1819 studies from database from 2019 to 2024 were identified, finally 10 studies were selected, the Statistical Package for the Social Sciences software was used for data analysis.
Results: The analyses across different geographic regions with 620,3969 patients with NAFLD, T2DM prevalence came out to be 15% among males, whereas 22.2% in females. A prevalence of 52.55% was noted in the obese population and 26.74% in lean individuals, with PCOS 43%, metabolic syndrome 75.3%, and sleep apnea 40% and various risk factors were also identified.
Conclusion: This review throws light on the nature of NAFLD, focusing on the need for increased awareness and screening among people at risk, strategies could help avert liver disease progression.
Downloads
References
Sood V, Alam S, Nagral A, Srivastava A, Deshmukh A, Bavdekar A, et al. Practice recommendations for metabolic dysfunction-associated steatotic liver disease by the Indian society of pediatricgastroenterology, hepatology and nutrition (ISPGHAN). Indian Pediatr. 2024;61(10):919-34. doi: 10.1007/s13312-024-3290-1, PMID 39297398
Younossi ZM, Zelber-Sagi S, Henry L, Gerber LH. Lifestyle interventions in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2023 Nov;20(11):708-22. doi: 10.1038/s41575-023-00800-4, PMID 37402873
Kang D, Zhao D, Ryu S, Guallar E, Cho J, Lazo M, et al. Perceived stress and non-alcoholic fatty liver disease in apparently healthy men and women. Sci Rep. 2020 Jan 8;10(1):38. doi: 10.1038/s41598-019- 57036-z, PMID 31913326
Masarone M, Rosato V, Dallio M, Gravina AG, Aglitti A, Loguercio C, et al. Role of oxidative stress in pathophysiology of nonalcoholic fatty liver disease. Oxid Med Cell Longev. 2018 Jun 11;2018:9547613. doi: 10.1155/2018/9547613, PMID 29991976
Page MJ. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Lipids Health Dis. 2023 Mar 15;22(1):41.
Egger M, Davey Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997 Sep 13;315(7109):629-34. doi: 10.1136/bmj.315.7109.629, PMID 9310563
Cao L, An Y, Liu H, Jiang J, Liu W, Zhou Y, et al. Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: A systematic review and meta-analysis. BMC Med. 2024 Mar 6;22(1):101. doi: 10.1186/s12916-024-03315-0, PMID 38448943
Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019 May;4(5):389-98. doi: 10.1016/S2468- 1253(19)30039-1, PMID 30902670
Ye Q, Zou B, Yeo YH, Li J, Huang DQ, Wu Y, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020 Aug;5(8):739-52. doi: 10.1016/S2468-1253(20)30077-7, PMID 32413340
Tang A, Ng CH, Phang PH, Chan KE, Chin YH, Fu CE, et al. Comparative burden of metabolic dysfunction in lean NAFLD vs non-lean NAFLD- A systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2023;21(7):1750-1760.e12. doi: 10.1016/j. cgh.2022.06.029, PMID 35863685
Liu Y, Wang W. Sex-specific contribution of lipid accumulation product and cardiometabolic index in the identification of nonalcoholic fatty liver disease among Chinese adults. Lipids Health Dis. 2022;21(1):8. doi: 10.1186/s12944-021-01617-3, PMID 35027066
Cholongitas E, Pavlopoulou I, Papatheodoridi M, Markakis GE, Bouras E, Haidich AB, et al. Epidemiology of nonalcoholic fatty liver disease in Europe: A systematic review and meta-analysis. Ann Gastroenterol. 2021;34(3):404-14. doi: 10.20524/aog.2021.0604, PMID 33948067
Manzano-Nunez R, Santana-Dominguez M, Rivera-Esteban J, Sena E, Bañares J, Frank Tacke NA. Fatty liver disease in patients with polycystic ovary syndrome: A systematic review, meta-analysis, and meta-regression J. Clin Mediterr. 2023 Jan 20;12(3):856.
Jullian-Desayes I, Trzepizur W, Boursier J, Joyeux-Faure M, Bailly S, Benmerad M, et al. Obstructive sleep apnea, chronic obstructive pulmonary disease and NAFLD: An individual participant data meta-analysis. Sleep Med. 2021 Jan;77:357-64. doi: 10.1016/j. sleep.2020.04.004, PMID 32843301
Zhang S, Liu Z, Yang Q, Hu Z, Zhou W, Ji G, et al. Impact of smoking cessation on non- alcoholic fatty liver disease prevalence: A systematic review and meta-analysis. BMJ Open. 2023;13(12):e074216. doi: 10.1136/bmjopen-2023-074216, PMID 38072477
Yuan M, He J, Hu X, Yao L, Chen P, Wang Z, et al. Hypertension and NAFLD risk: Insights from the NHANES 2017-2018 and Mendelian randomization analyses. Chin Med J (Engl). 2024 Feb 20;137(4):457-64. doi: 10.1097/CM9.0000000000002753, PMID 37455323
Lonardo A, Nascimbeni F, Mantovani A, Targher G. Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? J Hepatol. 2018 Feb;68(2):335-52. doi: 10.1016/j.jhep.2017.09.021, PMID 29122390
Shi T, Kobara H, Oura K, Masaki T. Mechanisms underlying hepatocellular carcinoma progression in patients with type 2 diabetes. J Hepatocell Carcinoma. 2021 Feb 11;8:45-55. doi: 10.2147/JHC. S274933, PMID 33604315
Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017 Jan;14(1):32-42. doi: 10.1038/ nrgastro.2016.147, PMID 27729660
Muzica CM, Sfarti C, Trifan A, Zenovia S, Cuciureanu T, Nastasa R, et al. Nonalcoholic fatty liver disease and type 2 diabetes mellitus: A bidirectional relationship. Can J Gastroenterol Hepatol. 2020 Dec 28;2020:6638306. doi: 10.1155/2020/6638306, PMID 33425804
Tricò D, Caprio S, Rosaria Umano GR, Pierpont B, Nouws J, Galderisi A, et al. Metabolic features of nonalcoholic fatty liver (NAFL) in obese adolescents: Findings from a multiethnic cohort. Hepatology. 2018 Oct;68(4):1376-90. doi: 10.1002/hep.30035, PMID 29665034
Hagström H, Nasr P, Ekstedt M, Hammar U, Stål P, Hultcrantz R, et al. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study. Hepatol Commun. 2018;2(1):48-57. doi: 10.1002/hep4.1124, PMID 29404512
Ebrahimi M, Seyedi SA, Nabipoorashrafi SA, Rabizadeh S, Sarzaeim M, Yadegar A, et al. Lipid accumulation product (LAP) index for the diagnosis of nonalcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis. Lipids Health Dis. 2023 Mar 15;22(1):41. doi: 10.1186/s12944-023-01802-6, PMID 36922815
Meijnikman AS, Lappa D, Herrema H, Aydin O, Krautkramer KA, Tremaroli V, et al. A systems biology approach to study nonalcoholic fatty liver (NAFL) in women with obesity. iScience. 2022 Aug 5;25(8):104828. doi: 10.1016/j.isci.2022.104828, PMID 35992074
Subudhi S, Drescher HK, Dichtel LE, Bartsch LM, Chung RT, Hutter MM, et al. Distinct hepatic gene-expression patterns of NAFLD in patients with obesity. Hepatol Commun. 2022 Jan;6(1):77-89. doi: 10.1002/hep4.1789, PMID 34558849
Balakrishnan M, Patel P, Dunn-Valadez S, Dao C, Khan V, Ali H, et al. Women have a lower risk of nonalcoholic fatty liver disease but a higher risk of progression vs men: A systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021 Jan;19(1):61-71.e15. doi: 10.1016/j. cgh.2020.04.067, PMID 32360810
Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses; 2004. Available from: https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp [Last accessed on 2021 Jan 25].
Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022 Sep;7(9):851-61. doi: 10.1016/S2468-1253(22)00165-0, PMID 35798021
Rocha AL, Faria LC, Guimarães TC, Moreira GV, Cândido AL, Couto CA, et al. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome: Systematic review and meta-analysis. J Endocrinol Invest. 2017 Dec;40(12):1279-88. doi: 10.1007/s40618- 017-0708-9, PMID 28612285
Musso G, Cassader M, Olivetti C, Rosina F, Carbone G, Gambino R. Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. Obes Rev. 2013;14(5):417-31. doi: 10.1111/obr.12020, PMID 23387384
Jung HS, Chang Y, Kwon MJ, Sung E, Yun KE, Cho YK, et al. Smoking and the risk of nonalcoholic fatty liver disease: A cohort study. Am J Gastroenterol. 2019 Mar;114(3):453-63. doi: 10.1038/s41395-018- 0283-5, PMID 30353055
Younossi ZM, Rinella ME, Sanyal AJ, Harrison SA, Brunt EM, Goodman Z, et al. From NAFLD to MAFLD: Implications of a premature change in terminology. Hepatology. 2021 Mar;73(3):1194-8. doi: 10.1002/hep.31420, PMID 32544255
Younossi ZM, Stepanova M, Younossi Y, Golabi P, Mishra A, Rafiq N, et al. Epidemiology of chronic liver diseases in the USA in the past three decades. Gut. 2020 Mar;69(3):564-8. doi: 10.1136/gutjnl-2019-318813, PMID 31366455
Eslam M, Sanyal AJ, George J, International Consensus Panel. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020 May;158(7):1999-2014.e1. doi: 10.1053/j.gastro.2019.11.312, PMID 32044314
Arendse LB, Danser AH, Poglitsch M, Touyz RM, Burnett JC, Llorens-Cortes C, et al. Novel therapeutic approaches targeting the renin-angiotensin system and associated peptides in hypertension and heart failure. Pharmacol Rev. 2019 Oct;71(4):539-70. doi: 10.1124/ pr.118.017129, PMID 31537750
Tsuneto A, Hida A, Sera N, Imaizumi M, Ichimaru S, Nakashima E, et al. Fatty liver incidence and predictive variables. Hypertens Res. 2010 Jun;33(6):638-43.
Aneni EC, Oni ET, Martin SS, Blaha MJ, Agatston AS, Feldman T, et al. Blood pressure is associated with the presence and severity ofnonalcoholic fatty liver disease across the spectrum of cardiometabolic risk. Martin J Hypertens. 2015 Jun;33(6):1207-14.
Ma C, Yan K, Wang Z, Zhang Q, Gao L, Xu T, et al. The association between hypertension and nonalcoholic fatty liver disease (NAFLD): literature evidence and systems biology analysis. Bioengineered. 2021;12(1):2187-202. doi: 10.1080/21655979.2021.1933302, PMID 34096467
Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: The state of the disease. Gastroenterology. 2020 May;158(7):1851-64. doi: 10.1053/j.gastro.2020.01.052, PMID 32061595
Dalmia D, Monga P. Possible genetic involvement in nonalcoholic fatty liver disease. Int J Curr Res. 2024;16(10):30278-82.
Li F, Ye J, Shao C, Zhong B. Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients: A systematic review and Meta-analysis. Lipids Health Dis. 2021 Feb 26;20(1):22. doi: 10.1186/ s12944-021-01440-w, PMID 33637088
Ahmed HH, Salem AM, Mohamed MR, Shahat AA, Khalil WK, Mohamed SH. Experimental evidences for the promising therapeutic role of Vitis vinifera seed extract against nonalcoholic steatohepatitis. Int J Pharm Pharm Sci. 2015;7(2):417-24.
Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55(7):434-8. doi: 10.1016/S0025- 6196(24)00530-5, PMID 7382552
Schaffner F, Thaler H. Nonalcoholic fatty liver disease. Prog Liver Dis. 1986;8:283-98. PMID 3086934
Published
How to Cite
Issue
Section
Copyright (c) 2025 BABU RAJENDRA PRASAD TR, LEENA JOSE, JAYAKRISHNAN KS, ANIKET KUMAR, JAMILA HAMEED
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
